Latest Period
Q1 2026
Security Snapshot
Journey Medical Corp - Common Stock (DERM) Institutional Ownership
CUSIP: 48115J109
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
70
Shares (Excl. Options)
11,773,873
Price
$4.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- DERM on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 11,773,873
- Total 13F value
- $55,217,591
- Portfolio coverage rank
- 0%
- Share change
- +243,351
- Value change
- -$1,855,627
- Number of holders
- 70
- Shares outstanding
- 21,352,124
- SEC-reported price per share
- $5.00
- Insider filing price
- $5.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DERM - Journey Medical Corp - Common Stock is tracked under CUSIP 48115J109.
- 70 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 76 to 70 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $84,985,269 to $55,217,591.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 70 institutions filings for Q1 2026.
Security key
48115J109
Latest holder period
Q1 2026
13F holders
70
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
DERM full holder history
Journey Medical Corp SEC filings
Journey Medical Corp company facts
Journey Medical Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 48115J109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
DERM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 10% | +47% | $16,554,951 | +$7,614,973 | 2,133,370 | +85% | Wasatch Advisors LP | 31 Mar 2026 |
| TANG CAPITAL MANAGEMENT LLC | 8% | $14,020,746 | 1,854,596 | TANG CAPITAL MANAGEMENT, LLC | 31 Mar 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.6% | $5,657,993 | 1,206,395 | Vanguard Capital Management | 31 Mar 2026 |
As of 31 Mar 2026, 70 institutional investors reported holding 11,773,873 shares of Journey Medical Corp - Common Stock (DERM). This represents 55% of the company’s total 21,352,124 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
53%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 10% | 2,133,370 | +62% | 0.07% | $10,005,505 |
| TANG CAPITAL MANAGEMENT LLC | 7.5% | 1,610,000 | -13% | 0.38% | $7,550,900 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | 1,082,080 | 0% | 0% | $5,074,955 |
| BlackRock, Inc. | 4.6% | 972,862 | +35% | 0% | $4,562,724 |
| Opaleye Management Inc. | 4.5% | 960,000 | -1.5% | 0.62% | $4,502,400 |
| J. Goldman & Co LP | 2.3% | 500,188 | -37% | 0.11% | $2,345,882 |
| Pale Fire Capital SE | 2.3% | 481,987 | +8.4% | 0.2% | $2,260,519 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 463,202 | +48% | 0% | $2,172,918 |
| UBS Group AG | 1.8% | 390,138 | +34% | 0% | $1,829,747 |
| MILLENNIUM MANAGEMENT LLC | 1.8% | 383,067 | -16% | 0% | $1,796,584 |
| Summit Financial, LLC | 1.8% | 379,807 | -2.7% | 0.02% | $1,781,295 |
| Ikarian Capital, LLC | 1.2% | 251,436 | 0% | 0.17% | $1,179,235 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 242,500 | -0.61% | 0% | $1,137,325 |
| STATE STREET CORP | 1.1% | 237,288 | +37% | 0% | $1,112,881 |
| Diametric Capital, LP | 0.92% | 196,412 | +280% | 0.24% | $921,172 |
| AMERICAN FINANCIAL GROUP INC | 0.84% | 180,000 | 0% | 0.31% | $844,200 |
| NORTHERN TRUST CORP | 0.7% | 149,978 | +60% | 0% | $703,397 |
| VANGUARD FIDUCIARY TRUST CO | 0.64% | 137,706 | 0% | 0% | $645,841 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.57% | 122,245 | 0% | 0% | $573,329 |
| ENVESTNET ASSET MANAGEMENT INC | 0.34% | 71,636 | +113% | 0% | $335,973 |
| GOLDMAN SACHS GROUP INC | 0.32% | 69,389 | +261% | 0% | $325,434 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.32% | 67,442 | 0% | 0.01% | $316,303 |
| Frec Markets, Inc. | 0.24% | 50,500 | 0.04% | $236,845 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.21% | 45,331 | +28% | 0% | $212,602 |
| LAZARD ASSET MANAGEMENT LLC | 0.21% | 44,898 | -28% | 0% | $210,572 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 11,773,873 | $55,217,591 | -$1,855,627 | $4.69 | 70 |
| 2025 Q4 | 11,022,797 | $84,985,269 | +$18,818,454 | $7.71 | 76 |
| 2025 Q3 | 8,692,790 | $61,930,042 | +$15,659,236 | $7.12 | 67 |
| 2025 Q2 | 6,494,302 | $46,629,314 | +$11,145,137 | $7.18 | 56 |
| 2025 Q1 | 5,017,760 | $29,603,817 | +$7,390,927 | $5.90 | 38 |
| 2024 Q4 | 3,813,405 | $14,909,751 | +$6,149,987 | $3.91 | 38 |
| 2024 Q3 | 2,156,982 | $12,186,357 | -$1,194,242 | $5.65 | 36 |
| 2024 Q2 | 2,360,259 | $13,310,203 | +$3,384,583 | $5.64 | 35 |
| 2024 Q1 | 1,816,385 | $6,678,973 | +$973,921 | $3.68 | 31 |
| 2023 Q4 | 1,341,390 | $7,982,763 | -$492,957 | $5.76 | 34 |
| 2023 Q3 | 2,135,266 | $5,850,655 | +$1,401,524 | $2.74 | 20 |
| 2023 Q2 | 1,652,825 | $2,627,537 | -$24,753 | $1.59 | 19 |
| 2023 Q1 | 1,668,350 | $2,620,320 | -$179,207 | $1.57 | 16 |
| 2022 Q4 | 2,672,478 | $5,131,893 | -$313,986 | $1.92 | 18 |
| 2022 Q3 | 1,878,524 | $4,621,000 | +$328,580 | $2.46 | 18 |
| 2022 Q2 | 1,759,431 | $6,580,100 | +$289,703 | $3.74 | 12 |
| 2022 Q1 | 1,644,289 | $7,940,000 | +$35,914 | $4.83 | 13 |
| 2021 Q4 | 1,627,492 | $8,756,000 | +$8,756,000 | $5.38 | 14 |